Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
K M Yasif Kayes SikdarDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0003-4958-2745
Ahmed ShalanDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Vincent CastejonDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Carly ChambersDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Samara Renae CoverleyDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Okhee YooDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0001-7285-1953
Md Khairul IslamDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0002-9333-6536
Tomislav SostaricDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0002-0154-4179
Lee Yong LimDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0002-7307-0742
Philip BurchamDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Cornelia LocherDepartment of Pharmacy and Centre for Optimisation of Medicines, School of Health and Clinical Sciences, University of Western Australia, Crawley, WA 6009, Australia.ORCID 0000-0001-8773-3036
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
CYP1A2 activity plays a critical role in the metabolism of drugs such as caffeine, clozapine, propranolol, and warfarin. In pharmacogenomic studies, caffeine is a probe drug of choice for CYP1A2 phenotyping. Due to the non-invasive nature of sampling, saliva is an alternative biofluid to plasma for monitoring caffeine levels. This study reports on a validated HPTLC method for quantifying salivary caffeine levels, which can support future studies on CYP1A2 phenotyping employing caffeine as a probe drug. The HPTLC method, using silica gel 60 F254 plates and acetone/toluene/chloroform (4:3:3,
Indexed as
CaffeineSalivaChromatography, High Pressure LiquidChromatography, Thin LayerCytochrome P-450 CYP1A2HumansReproducibility of ResultsCaffeineCYP1A2 protein, humanCytochrome P-450 CYP1A2caffeineHPTLCprobe drugsalivavalidation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of a Validated High-Performance Thin-Layer Chromatography (HPTLC) Analysis Protocol for Salivary Caffeine Used as a Probe Drug. · full record | OpenQuestion